Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2024-07-12 Major Shareholding Noti…
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BIOS_PR_2024-07_Transparency Notification_Pomi_FR_FINAL.pdf
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE" (Press Release – Regulated Information) and announces the receipt of a transparency notification regarding a change in significant shareholding (franchissement de seuil passif de participation de 5%). This type of filing, which reports changes in ownership thresholds by individuals or entities, directly corresponds to the definition of Major Shareholding Notification. The French term 'Notification de transparence' is the equivalent of a major shareholding disclosure. Therefore, the correct classification is MRQ (Major Shareholding Notification).
2024-07-12 French
BioSenic - AGO 2024 - Signed.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a 'Procès-verbal' (minutes) of an Annual General Meeting (AGM) held on July 12, 2024, for the company BioSenic. It details the attendance, the agenda items (such as approval of annual accounts, discharge of directors, and remuneration reports), and the specific voting results for each resolution. Since it contains the official record of the voting results and decisions made at the general meeting, it falls under the category of Declaration of Voting Results & Voting Rights Announcements.
2024-07-12 French
BIOS_PR_Patent_ATO-Cu-sepsis_EN_Final.pdf
Regulatory Filings Classification · 95% confidence The document is explicitly titled "PRESS RELEASE – PRIVILEGED INFORMATION" and dated 05/07/2024. It announces key business developments, specifically the extension of a key patent (composition-of-matter patent family) in the United States and provides high-level updates on clinical progress and intellectual property strategy. This format, focusing on immediate, material, non-financial news, aligns best with an Earnings Release (ER) if it were summarizing financial results, but since it focuses on a specific corporate event (patent extension) and is structured as a press release, it is most likely a general corporate announcement. Given the options, it is not a full 10-K, AR, or IR. It is not a Call Transcript (CT) or Investor Presentation (IP). It is not a formal regulatory filing like a DIRS or MRQ. Since it announces a significant corporate/IP event via a press release, and it is not a specific financial report, the most appropriate general category for a significant, timely corporate announcement that isn't strictly financial results or a specific regulatory form is often captured by the Earnings Release category if it's tied to a reporting period, or RNS if it's a general regulatory announcement. However, this document is a detailed announcement of a strategic/IP event, not just a brief notice. It is too detailed for a simple RPA. Given the content is a major corporate update (patent extension, clinical pipeline status) released via a press release, it functions similarly to an Earnings Release (ER) in terms of being a primary communication of recent material developments, even if financial figures are absent. If it were purely a regulatory filing notice, RNS would fit, but this is a substantive announcement. Since it details strategic progress and IP protection, it is a significant corporate update. In the absence of a specific 'Corporate Update' code, and noting that ERs often contain strategic commentary alongside results, I will check other options. It is not a DIV, CAP, or TAR. It is a detailed announcement of corporate progress. If this were released alongside quarterly results, it would be part of the ER package. If it is standalone, it is a significant corporate announcement. Given the options, and its nature as a primary communication of material news, ER is plausible, but RNS (Regulatory Filings/General Announcement) is often used for non-standard, material press releases. Since the document is substantial (over 10,000 characters) and provides deep context on the patent and pipeline, it is more than just a brief notice, making RPA less likely. I will classify it as a general Regulatory Filing (RNS) as it is a formal announcement of a material event (patent filing) that doesn't fit the other specific financial/governance codes, acting as a catch-all for significant, non-standard disclosures.
2024-07-05 English
BIOS_PR_Patent_ATO-Cu-sepsis_FR_Final.pdf
Regulatory Filings Classification · 100% confidence The document is titled "COMMUNIQUE DE PRESSE – INFORMATION PRIVILEGIEE" (Press Release – Privileged Information) and is dated 05/07/2024. It announces a specific corporate action: Medsenic (a subsidiary of BioSenic SA) extending a key patent to the United States (USPTO filing). This type of announcement, detailing intellectual property strategy, clinical pipeline updates, and management commentary, is characteristic of a general corporate news release. Since it is not a full financial report (10-K, IR), a specific regulatory filing form (like DIRS, DIV, or DEF 14A), or a transcript (CT), the most appropriate classification is the general category for regulatory announcements that do not fit elsewhere, which is Regulatory Filings (RNS). Although it discusses R&D and IP, it is an announcement *about* these activities, not the detailed report itself.
2024-07-05 French
BIOS_PR _New Phebra licensing and MDA on cGvHD _EN_FINAL.pdf
Regulatory Filings Classification · 95% confidence The document is titled 'PRESS RELEASE – PRIVILEGED INFORMATION 02/07/2024' and announces a significant business event: the signing of new licensing and commercialization agreements between Medsenic (a subsidiary) and Phebra Pty Ltd. It details the terms, impact on future financing (Phase 3 trial), and strategic implications. This type of announcement, detailing operational and commercial milestones, is characteristic of an Earnings Release (ER) if it were summarizing financial results, or a Regulatory Filing (RNS) if it were a general announcement. However, given the focus on commercial agreements, financing implications, and strategic updates, it strongly aligns with an Earnings Release (ER) which often includes key operational updates alongside financial highlights, or potentially a general Regulatory Filing (RNS). Since it is a formal press release announcing a major business development rather than a full financial report (like 10-K or IR), and it is not a transcript (CT) or a specific management discussion (MDA), the most appropriate classification for a significant, time-sensitive business update released via press release is Earnings Release (ER), as these often contain operational news alongside results, or RNS as a general regulatory announcement. Given the content is primarily about a commercial agreement and its impact on financing, it fits best under the general category for significant, non-standard regulatory announcements, which is RNS, or ER if it is tied to a reporting period. Since it is a standalone press release announcing a deal, RNS is the safest general classification, but ER often covers such material news. Let's re-evaluate based on definitions. It is not a formal financial report (10-K, IR). It is not a transcript (CT). It is not a management discussion (MDA). It is a press release announcing a material event. This often falls under RNS (Regulatory Filings - general fallback) or ER (Earnings Release - if it accompanies results, which is not explicitly stated, but press releases are the format). Since it is a press release announcing a material event, and RNS is the fallback for miscellaneous filings, I will use RNS. However, if this were released around a quarterly period, ER would be plausible. Given the lack of explicit financial results summary, RNS is the most accurate fit for a material, non-standard announcement.
2024-07-02 English
BIOS_PR _New Phebra licensing and MDA on cGvHD _FR_FINAL.pdf
Regulatory Filings Classification · 100% confidence The document is titled "COMMUNIQUE DE PRESSE – INFORMATION PRIVILEGIEE" and is dated July 2, 2024. It announces a significant business event: the signing of new global license, supply, and commercialization agreements between Medsenic (a subsidiary of BioSenic) and Phebra Pty Ltd regarding the oral formulation of arsenic trioxide (OATO) for cGvHD treatment. This type of announcement, detailing strategic business developments, partnerships, and material agreements, is characteristic of a press release intended for immediate public disclosure. Since it is not a full annual report (10-K), a quarterly report (IR), a formal earnings release (ER), or a specific regulatory filing like a Director's Dealing (DIRS) or Capital Change (SHA), it best fits the category for general regulatory announcements or press releases that don't fit elsewhere. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general, material press release, although 'Capital/Financing Update' (CAP) or 'M&A Activity' (TAR) might be considered if the focus was purely on fundraising or a takeover, which it is not. The core is a strategic partnership announcement. RNS serves as the best general regulatory/press release category here.
2024-07-02 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.